AG-120 (ivosidenib), a first in-class mutant IDH1 inhibitor, promotes morphologic changes and upregulates liver-specific genes in IDH1 mutant cholangiocarcinoma

被引：3
|
作者：
Ishii, Yuko [1 ]
Sigel, Carlie [2 ]
Lowery, Maeve A. [2 ]
Goyal, Lipika [3 ]
Gliser, Camelia [1 ]
Jiang, Liewen [1 ]
Pandya, Susan [1 ]
Bin Wu [1 ]
Choe, Sung [1 ]
Deshpande, Vikram [3 ]
机构：
[1] Agios Pharmaceut Inc, Cambridge, MA USA
[2] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[3] Massachusetts Gen Hosp, Boston, MA 02114 USA
来源：
MOLECULAR CANCER THERAPEUTICS | 2018年 / 17卷 / 01期
关键词：
D O I：
10.1158/1535-7163.TARG-17-A071
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A071
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Molecular Profiling and Relationship with Clinical Response in Patients with IDH1 Mutation-Positive Hematologic Malignancies Receiving AG-120, a First-in-Class Potent Inhibitor of Mutant IDH1, in Addition to Data from the Completed Dose Escalation Portion of the Phase 1 Study
    DiNardo, Courtney
    de Botton, Stephane
    Pollyea, Daniel A.
    Stein, Eytan M.
    Fathi, Amir T.
    Roboz, Gail J.
    Collins, Robert
    Swords, Ronan T.
    Flinn, Ian W.
    Altman, Jessica K.
    Tallman, Martin S.
    Kantarjian, Hagop M.
    Derti, Adnan
    Goldwasser, Meredith
    Prahl, Malia
    Wu, Bin
    Yen, Katherine
    Agresta, Sam
    Stone, Richard M.
    BLOOD, 2015, 126 (23)
  • [32] A PHASE 1, OPEN-LABEL, PERIOPERATIVE STUDY OF IVOSIDENIB (AG-120) AND VORASIDENIB (AG-881) IN RECURRENT IDH1 MUTANT, LOW-GRADE GLIOMA: UPDATED RESULTS
    Mellinghoff, Ingo
    Cloughesy, Timothy
    Wen, Patrick
    Taylor, Jennie
    Maher, Elizabeth
    Arrillaga-Romany, Isabel
    Peters, Katherine
    Choi, Changho
    Ellingson, Benjamin
    Lin, Alexander
    Thakur, Sunitha
    Nicolay, Brandon
    Lu, Min
    Le, Kha
    Yin, Feng
    Tai, Feng
    Schoenfeld, Steven
    Pandya, Shuchi S.
    Hassan, Islam
    Steelman, Lori
    Clarke, Jennifer
    NEURO-ONCOLOGY, 2019, 21 : 28 - 28
  • [33] Crystal structures of pan-IDH inhibitor AG-881 in complex with mutant human IDH1 and IDH2
    Ma, Rui
    Yun, Cai-Hong
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2018, 503 (04) : 2912 - 2917
  • [34] AG-120, an Oral, Selective, First-in-Class, Potent Inhibitor of Mutant IDH1, Reduces Intracellular 2HG and Induces Cellular Differentiation in TF-1 R132H Cells and Primary Human IDH1 Mutant AML Patient Samples Treated Ex Vivo
    Hansen, Erica
    Quivoron, Cyril
    Straley, Kim
    Lemieux, Rene M.
    Popovici-Muller, Janeta
    Sadrzadeh, Hossein
    Fathi, Amir T.
    Gliser, Camelia
    David, Muriel
    Saada, Veronique
    Micol, Jean-Baptiste
    Bernard, Olivier
    Dorsch, Marion
    Yang, Hua
    Su, Michael
    Agresta, Sam
    de Botton, Stephane
    Penard-Lacronique, Virginie
    Yen, Katharine
    BLOOD, 2014, 124 (21)
  • [35] EVALUATION OF THE PHARMACOKINETICS OF IVOSIDENIB, AN ORAL, TARGETED INHIBITOR OF MUTANT IDH1, IN HEALTHY JAPANESE AND CAUCASIAN SUBJECTS.
    Fan, B.
    Cohen, M.
    Nabhan, S.
    Liu, H.
    Liu, G.
    Bowden, C.
    Yang, H.
    Dai, D.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 : S57 - S57
  • [36] Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma
    Tap, William D.
    Villalobos, Victor M.
    Cote, Gregory M.
    Burris, Howard
    Janku, Filip
    Mir, Olivier
    Beeram, Murali
    Wagner, Andrew J.
    Jiang, Liewen
    Wu, Bin
    Choe, Sung
    Yen, Katharine
    Gliser, Camelia
    Fan, Bin
    Agresta, Sam
    Pandya, Shuchi S.
    Trent, Jonathan C.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15) : 1693 - +
  • [37] Phase 1 study of AG-881, an inhibitor of mutant IDH1/IDH2, in patients with advanced IDH-mutant solid tumors, including glioma
    Mellinghoff, Ingo K.
    Penas-Prado, Marta
    Peters, Katherine B.
    Cloughesy, Timothy Francis
    Burris, Howard A.
    Maher, Elizabeth A.
    Janku, Filip
    Cote, Gregory Michael
    De La Fuente, Macarena Ines
    Clarke, Jennifer
    Steelman, Lori
    Le, Kha
    Zhang, Yanwei
    Sonderfan, Alison
    Hummel, Diana
    Schoenfeld, Steven
    Yen, Katharine
    Pandya, Shuchi Sumant
    Wen, Patrick Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [38] Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors
    Bin Fan
    Ingo K. Mellinghoff
    Patrick Y. Wen
    Maeve A. Lowery
    Lipika Goyal
    William D. Tap
    Shuchi S. Pandya
    Erika Manyak
    Liewen Jiang
    Guowen Liu
    Tara Nimkar
    Camelia Gliser
    Molly Prahl Judge
    Sam Agresta
    Hua Yang
    David Dai
    Investigational New Drugs, 2020, 38 : 433 - 444
  • [39] Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors
    Fan, Bin
    Mellinghoff, Ingo K.
    Wen, Patrick Y.
    Lowery, Maeve A.
    Goyal, Lipika
    Tap, William D.
    Pandya, Shuchi S.
    Manyak, Erika
    Jiang, Liewen
    Liu, Guowen
    Nimkar, Tara
    Gliser, Camelia
    Judge, Molly Prahl
    Agresta, Sam
    Yang, Hua
    Dai, David
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (02) : 433 - 444
  • [40] A first-in-human phase 1 study of LY3410738, a covalent inhibitor of mutant IDH1 and IDH2, as monotherapy and in combination with cisplatin and gemcitabine in advanced IDH-mutant cholangiocarcinoma
    Harding, J.
    Ikeda, M.
    Goyal, L.
    Rodon, J.
    Bai, L.
    Oh, D.
    Park, J.
    Chen, L.
    Ueno, M.
    Liao, C.
    Kondo, S.
    Cosman, R.
    Yokota, T.
    Shroff, R.
    Satoh, T.
    Palmieri, L.
    Hollebecque, A.
    Adeva, J.
    Bender, M.
    Liu, H.
    Macarulla, T.
    ANNALS OF ONCOLOGY, 2023, 34 : S161 - S161
12345